Cancer Research – Computational Biology

Rutgers Cancer Institute of New Jersey invites applications for a **research faculty position with interests in CAR-T cell therapy and computational biology**. The successful candidate will be part of the laboratory of Christian Hinrichs, the Chief of the Section of Cancer Immunotherapy, and Co-Leader of the newly established Duncan and Nancy MacMillan Cancer Immunology and Metabolism Center of Excellence. The Center is built on our existing strengths in cancer metabolism and immunological research in partnership with Princeton University, and its clinical translation through our robust CAR-T therapy program with onsite GMP manufacturing and first-in-human clinical trials. The research program is based on an iterative bench-to-bedside strategy of investigator-initiated research in which laboratory discovery drives clinical trials, and clinical trials drive laboratory research. This is an exciting opportunity to join a developing world-class cancer immunology and immunotherapy program and a cellular therapy center of excellence.

Rutgers Cancer Institute of New Jersey is an NCI-designated, comprehensive and consortium cancer center that includes faculty members from across Rutgers University (including Rutgers-Robert Wood Johnson Medical School and Rutgers Biomedical and Health Sciences) and Princeton University. We are a leader in basic, clinical, prevention, and public health science, offering world-class quality cancer care providing the most advanced medicines and treatment options for patients in our health system network across the state. We are easily accessible to Manhattan, Newark Airport, and Philadelphia. Visit our website at www.cinj.org.

Research faculty are expected to establish an innovative, collaborative research program addressing important, fundamental questions. The goal of the research is to develop and apply computational genomics and bioinformatics tools based on next generation sequencing data for better understanding of cancer response and resistance to immunotherapy. The Hinrichs group has particular interest in defining the landscape of tumor-intrinsic, immune-related gene defects that mediate immunotherapy resistance. This research includes study of somatic mutations, copy number variants, gene expression profiling, tumor heterogeneity, single cell genomics, and tumor systems biology. There will be opportunities to work in an interdisciplinary team both in clinical and laboratory research settings on a variety of high impact, cutting edge projects. All candidates must have a Ph.D. and/or M.D., or equivalent graduate degree, and outstanding academic credentials. Rank will be commensurate with experience.

To apply, please send CV and cover letter to CINJCellTherapy@cinj.rutgers.edu.